SpringWorks Therapeutics Appoints Dr. Martin Mackay To Its Board Of Directors
SpringWorks Therapeutics, Inc., a biopharmaceutical company focusing on rare diseases and cancer, has appointed Martin Mackay, Ph.D., to its Board of Directors. Dr. Mackay brings over 30 years of R&D experience from leading roles at Pfizer, AstraZeneca, and Alexion. Saqib Islam, CEO of SpringWorks, expressed enthusiasm about Dr. Mackay's appointment, citing his expertise in rare diseases and his global leadership experience in R&D as invaluable assets for advancing SpringWorks' pipeline and mission.
Dr. Mackay, co-founder and Executive Chairman of Rallybio, previously served as EVP and Head of R&D at Alexion and President of R&D at AstraZeneca, among other senior roles at Pfizer. He currently serves on the boards of Charles River Laboratories and Novo Nordisk. Dr. Mackay is eager to contribute to SpringWorks' efforts in developing transformative therapies for patients with severe diseases. SpringWorks' precision medicine approach has led to its first FDA-approved therapy, OGSIVEO® (nirogacestat), for desmoid tumors and a robust pipeline in solid tumors and hematological cancers.
Comments
Post a Comment